Skip to main content
Caplight Logo









Hepta Bio

Hepta Bio

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.hepta.bio/

Last Round

Seed

Nov 5, 2025

Total Funding Raised

$6.7M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Hepta Bio is a biotechnology company that develops a liquid biopsy and AI platform to read the cell-free DNA epigenome and detect organ-specific signals of chronic disease, with an initial focus on metabolic dysfunction-associated steatohepatitis (MASH).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical AI, Precision Medicine, Healthcare Analytics, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service, Government Contracts

AI Layer

Application

Keywords

liquid biopsynon-invasive diagnosticsMASHepigenomicscell-free DNAcfDNAAI diagnosticsliver biopsy alternativechronic disease detectionliver disease detectionprecision medicinemolecular diagnosticsMetabolic Dysfunction-Associated Steatohepatitisclinical trial diagnostics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hepta Bio Comparables

Compare Hepta Bio with similar companies based on industry and business-model similarity.

Hepta Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AGED Diagnostics
89%
Glycotest, Inc.
75%
Senseera
71%

Hepta Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedNov 5, 2025

Key People

Founding team and executive leadership

Soheil Damangir

Co-Founder and CTO

Founding Team

Hamed Amini

Co-founder CEO

Founding Team

Hepta Bio Investors

Notable investors and investment history

Hepta Bio investors
InvestorRounds
SeaX VenturesSeed
AME Cloud VenturesSeed
Alumni VenturesSeed
Felicis VenturesSeed
Illumina VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 24, 2026

    Grew 100% QoQ from 3 to 6 employees.

  • Apr 19, 2026

    Monthly visitors increased 35% MoM, reaching 2.8K.

Hepta Bio Filings

Explore SEC and related filing metadata, where available.

Hepta Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Hepta Bio's valuation, stock price, and market status.

Is Hepta Bio a public or private company?

Hepta Bio is a private company.

What is the current stock price of Hepta Bio?

Hepta Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Hepta Bio worth (valuation)?

Valuation information for Hepta Bio is not publicly available.

Can I buy Hepta Bio stock?

Hepta Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Hepta Bio's last funding round?

Hepta Bio's most recent funding round was Seed on November 5, 2025.

Who are the main investors in Hepta Bio?

Key investors in Hepta Bio include Felicis Ventures, Illumina Ventures.

Will Hepta Bio IPO soon?

No public IPO plans have been announced for Hepta Bio.

How can I track Hepta Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Hepta Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range5
Year Founded2021
Last FundingNov 5, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?